Compare Williams Companies Inc (WMB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Williams Companies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Williams Companies Inc trades at $72.67 (market cap $88.48B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Williams Companies Inc is far larger — about 8.8× State Street SPDR S&P Biotech ETF's market cap, and Williams Companies Inc pays a 2.9% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Williams Companies Inc for 58 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| WMB | XBI | |
|---|---|---|
Market Cap | $88.48B | $10.11B |
Volume | 9,280,680 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $79.40 | $169.55 |
52-Week Low | $56.51 | $104.99 |
Typical Hold Time | 58 Days | 38 Days |
Enterprise Value | $119.11B | — |
Dividend Yield | 2.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WMB trades at $72.34, up 1.23% with strong technical momentum and bullish analyst sentiment. The stock shows solid fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while technical indicators signal bullish momentum with support at $71-72 levels. The company benefits from natural gas demand growth driven by AI data center expansion and maintains stable fee-based revenue streams.
Outlook remains positive with 79% analyst buy ratings and $87.27 consensus target, representing 21% upside. Key opportunities include AI-driven natural gas demand and strategic acquisitions, while risks involve energy market volatility and high debt levels. The stock offers compelling value with strong cash flow generation and dividend growth potential.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
